Literature DB >> 16804982

Eradication of H pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy.

Lian Zhang1, Lin Shen, Jun-Ling Ma, Kai-Feng Pan, Wei-Dong Liu, Jie Li, Shu-Dong Xiao, San-Ren Lin, Meinhard Classen, Wei-Cheng You.   

Abstract

AIM: To compare the one-day quadruple therapy with a standard 7-d triple therapy for H pylori eradication in a rural population of China.
METHODS: A total of 396 patients with (13)C-urea breath test positive for H pylori were assigned into two groups: 239 patients received one-day quadruple therapy (amoxicillin 2000 mg qid; metronidazole 500 mg qid; bismuth citrate 900 mg qid and lansoprazole 60 mg once daily) and 157 patients received 7-d standard triple therapy (amoxicillin 1000 mg bid; clarithromycin 500 mg bid and lansoprazole 30 mg bid). All the patients underwent a (13)C-UBT to assess the eradication of H pylori infection six weeks after treatment.
RESULTS: Two hundred and twenty-nine patients completed the one-day therapy (95.8%) and 148 patients completed the 7-d therapy (94.2%). The one-day therapy eradicated H pylori infection in 64 patients (27.95%). In contrast, 103 patients (69.59%) were H pylori negative after the 7-d therapy (P < 0.01).
CONCLUSION: This pilot study suggests there is no beneficial effect of the one-day therapy in treatment of H pylori infection compared with the 7-d standard therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16804982      PMCID: PMC4087945          DOI: 10.3748/wjg.v12.i24.3915

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  18 in total

1.  Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data.

Authors:  M H Gail; W C You; Y S Chang; L Zhang; W J Blot; L M Brown; F D Groves; J P Heinrich; J Hu; M L Jin; J Y Li; W D Liu; J L Ma; S D Mark; C S Rabkin; J F Fraumeni; G W Xu
Journal:  Control Clin Trials       Date:  1998-08

Review 2.  Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG).

Authors:  P Malfertheiner; F Mégraud; C O'Morain; D Bell; G Bianchi Porro; M Deltenre; D Forman; G Gasbarrini; B Jaup; J J Misiewicz; J Pajares; M Quina; E Rauws
Journal:  Eur J Gastroenterol Hepatol       Date:  1997-01       Impact factor: 2.566

Review 3.  Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model.

Authors:  D Y Graham
Journal:  Gastroenterology       Date:  1997-12       Impact factor: 22.682

4.  Helicobacter pylori and gastric cancer: state of the art.

Authors:  P Correa
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1996-06       Impact factor: 4.254

5.  Antibiotic resistance of Helicobacter pylori strains in Japanese children.

Authors:  Seiichi Kato; Shigeru Fujimura; Hirokazu Udagawa; Toshiaki Shimizu; Shunichi Maisawa; Kyoko Ozawa; Kazuie Iinuma
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

Review 6.  Helicobacter pylori infection is the primary cause of gastric cancer.

Authors:  D Y Graham
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

7.  Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea.

Authors:  J J Kim; R Reddy; M Lee; J G Kim; F A El-Zaatari; M S Osato; D Y Graham; D H Kwon
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

8.  Noninvasive detection of Helicobacter pylori infection in clinical practice: the 13C urea breath test.

Authors:  P D Klein; H M Malaty; R F Martin; K S Graham; R M Genta; D Y Graham
Journal:  Am J Gastroenterol       Date:  1996-04       Impact factor: 10.864

9.  Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.

Authors:  Benjamin Chun-Yu Wong; Shiu Kum Lam; Wai Man Wong; Jian Shun Chen; Ting Ting Zheng; Rui E Feng; Kam Chuen Lai; Wayne Hsing Cheng Hu; Siu Tsan Yuen; Suet Yi Leung; Daniel Yee Tak Fong; Joanna Ho; Chi Kong Ching; Jun Shi Chen
Journal:  JAMA       Date:  2004-01-14       Impact factor: 56.272

Review 10.  The treatment of Helicobacter pylori infection in the management of peptic ulcer disease.

Authors:  J H Walsh; W L Peterson
Journal:  N Engl J Med       Date:  1995-10-12       Impact factor: 91.245

View more
  8 in total

Review 1.  Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis.

Authors:  Ben Wang; Zhi-Fa Lv; You-Hua Wang; Hui Wang; Xiao-Qun Liu; Yong Xie; Xiao-Jiang Zhou
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

2.  Methylation of GATA-4 and GATA-5 and development of sporadic gastric carcinomas.

Authors:  Xian-Zi Wen; Yoshimitsu Akiyama; Kai-Feng Pan; Zhao-Jun Liu; Zhe-Ming Lu; Jing Zhou; Lian-Kun Gu; Cai-Xuan Dong; Bu-Dong Zhu; Jia-Fu Ji; Wei-Cheng You; Da-Jun Deng
Journal:  World J Gastroenterol       Date:  2010-03-14       Impact factor: 5.742

Review 3.  Is short-term therapy really sufficient to eradicate Helicobacter pylori infection?

Authors:  Ning Zhou; Wei-xing Chen; Wei Zhang; Lan Li; Xi Jin; You-ming Li
Journal:  J Zhejiang Univ Sci B       Date:  2010-09       Impact factor: 3.066

Review 4.  Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China.

Authors:  Hong Lu; Wei Zhang; David Y Graham
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-10       Impact factor: 2.566

5.  Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond.

Authors:  David Y Graham; Hong Lu; Yoshio Yamaoka
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.

Authors:  Quan Zhou; Xiao-Feng Yan; Zhong-Miao Zhang; Wen-Sheng Pan; Su Zeng
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

7.  Prevalence of A2143G mutation of H. pylori-23S rRNA in Chinese subjects with and without clarithromycin use history.

Authors:  Zhuoqi Liu; Jing Shen; Lian Zhang; Lin Shen; Qiang Li; Baozhen Zhang; Jing Zhou; Liankun Gu; Guoshuang Feng; Junling Ma; Wei-Cheng You; Dajun Deng
Journal:  BMC Microbiol       Date:  2008-05-28       Impact factor: 3.605

8.  Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection.

Authors:  Ming-Cheh Chen; Wei-Yi Lei; Jen-Shung Lin; Chih-Hsun Yi; Deng-Chyang Wu; Chi-Tan Hu
Journal:  Biomed Res Int       Date:  2014-06-05       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.